Ocugen's Chairman, CEO and Co-founder, Shankar Musunuri ,Ph.D., MBA, provides an update on OCU400 and other ongoing trials, why the eye is a good target for gene therapy, the outlook for retinal gene therapy, and more.
Umoja Biopharma’s Dr. Andrew Scharenberg joined me as my guest on a recent episode of Cell & Gene: The Podcast to discuss the evolution of in vivo CAR-T cell therapeutics. Here are highlights from our conversation.
LSPA's Life Science Future event included a plenary session featuring Jim Wilson Ph.D., M.D., Director, Gene Therapy Program Professor of Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania. Here's a recap of that session.